Pfizer: Carcinoma, Renal Cell trials

The registry lists 80 Carcinoma, Renal Cell studies with Pfizer as lead sponsor. 1 are open to participants now and 54 have results posted.

Phase 1 21Phase 2 15Phase 3 5Phase 4 1No phase 42(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingNCT07227415Phase 1/2
• A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.CompletedNCT05745142Results posted
• Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).TerminatedNCT05534789Results posted
• A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedNCT05363072Results posted
• Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedNCT05061537Phase 1Results posted
• Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)CompletedNCT05012865Results posted
• To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell CarcinomaCompletedNCT04682587Results posted
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
• Treatment Resistance Following Anti-cancer TherapiesTerminatedNCT04436120Not applicableResults posted
• Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCCCompletedNCT04375150Results posted
• Retrospective Study on Referral Patterns for High Risk Patients Post NephrectomyCompletedNCT04309617Results posted
• Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) TreatmentsCompletedNCT04175262Results posted
• A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)CompletedNCT04115189Results posted
• Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line SunitinibCompletedNCT04076787Results posted
• REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMACompletedNCT03916458Results posted
• PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsTerminatedNCT03685591Phase 1Results posted
• "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"CompletedNCT03538717Results posted
• Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.TerminatedNCT03140176Results posted
• Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line TreatmentCompletedNCT02789137Results posted
• Clinical Outcome Of Advanced Renal Cell Carcinoma In TaiwanCompletedNCT02776644Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine PracticeCompletedNCT02533258Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCCCompletedNCT02315755Results posted
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
• Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First LineCompletedNCT02187042Results posted
• Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South KoreaCompletedNCT02156895Results posted
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results posted
• A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall SurvivalCompletedNCT01917214Results posted
• Sutent Rechallenge In mRCC PatientsCompletedNCT01827254Results posted
• PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell CarcinomaTerminatedNCT01441414Phase 2Results posted
• INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With TemsirolimusCompletedNCT01367457Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)CompletedNCT01210482Results posted
• Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012CompletedNCT01056263Results posted
• Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With SutentCompletedNCT00836745Results posted
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney CancerCompletedNCT00835978Phase 2Results posted
• Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)CompletedNCT00716625Results posted
• Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4Results posted
• Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®CompletedNCT00684645Results posted
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
• Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)CompletedNCT00569946Phase 2Results posted
• Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell CarcinomaCompletedNCT00494091Phase 2Results posted
• Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line SunitinibCompletedNCT00474786Phase 3Results posted
• SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Results posted
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
• Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney CancerCompletedNCT00338884Phase 2Results posted
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell CancerCompletedNCT00282048Phase 2Results posted
• Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)CompletedNCT00267748Phase 2Results posted
• Study of SU011248 in Patients With Advanced Kidney CancerCompletedNCT00254540Phase 2Results posted
• Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell CarcinomaCompletedNCT00113529Phase 1/2Results posted
• SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell CarcinomaCompletedNCT00089648Phase 2Results posted
• SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell CarcinomaCompletedNCT00083889Phase 3Results posted
• A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.CompletedNCT00077974Phase 2Results posted
• Study Evaluating Interferon And CCI-779 In Advanced Renal Cell CarcinomaCompletedNCT00065468Phase 3Results posted
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).CompletedNCT05858749
• An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UKCompletedNCT05394493
• Axitinib Therapy Management StudyWithdrawnNCT04555603
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.TerminatedNCT04152018Phase 1
• A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1
• Safety Study of SGN-CD70A in Cancer PatientsCompletedNCT02216890Phase 1
• Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life SettingCompletedNCT02184416
• A Post Marketing Surveillance As Required By Philippine Food And Drug AdministrationWithdrawnNCT01781442
• A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell CarcinomaTerminatedNCT01677390Phase 1
• Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line TreatmentNo longer availableNCT01473043
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
• Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.CompletedNCT01339962
• Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644
• Cost Effectiveness Of Sunitinib In Central America And CaribbeanTerminatedNCT01033981
• A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell CarcinomaCompletedNCT01015911Phase 1
• Study Evaluating Renal Cell Carcinoma Risk FactorsCompletedNCT00927043
• Study In Patients With Kidney Cancer Treated With SutentCompletedNCT00873210
• A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell CarcinomaTerminatedNCT00417677Phase 1/2
• Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaApproved for marketingNCT00130897
• CPG 7909 in Patients Wih Stage IV Renal Cell CancerCompletedNCT00043407Phase 1/2
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)CompletedNCT00043368Phase 2